According to documents from the Hong Kong Stock Exchange, Biocytogen has submitted IPO application, and Goldman Sachs and CICC are joint sponsors.

Biocytogen is a clinical stage biotechnology and preclinical research service company already generating revenues. It has built a high-throughput in vivo antibody discovery platform, proprietary gene editing technologies, transgenic mouse platform, and comprehensive animal patient models. The world's first large-scale in vivo antibody discovery and screening program initiated by Biocytogen is expected to become the fountain of a large number of first-in-class antibodies or best-in-class antibodies against new and/or difficult drug targets.

Source: https://baijiahao.baidu.com/s?id=1709478468916000816&wfr=spider&for=pc